Research line 'Hemophilia, Von Willebrand disease and allied coagulation disorders'
Research line 'Hemophilia, Von Willebrand disease and allied coagulation disorders'
The Van Creveldkliniek holds an international leading position in scientific research in the field of hemophilia, Von Willebrand disease and allied coagulation disorders. This includes innovative therapeutic and gene therapy studies, studies in joint damage, self management and adherence, sports, hemophilia carriers and registries.
Research includes both studies that are initiated by our researchers and studies that are being performed on behalf of pharmaceutical companies. An overview of currently active studies at the Van Creveldkliniek is shown in the table below.
Study | Patient population | Description |
---|---|---|
ADVANCE-AF | Hemophilia patients with cardiovascular diseases | Registry of cardiovascular events in hemophilia patients to determine optimal treatment regimen. |
BEGIN | Adults with severe hemophilia A | Cross-sectional study to detect sub-clinical joint bleeds and arthritis. |
CVD | Hemophilia A and B patients aged 30 years and older | Prospective study with 10 year follow-up to determine the occurence of cardio-vascular diseases. |
DISTRACTIE | Adults with hemophilia A and B with severe arthropathy of the ankle | Evaluation of the clinical efficacy of ankle joint distraction in hemophilia patients with severe arthropathy of the ankle. |
DosEmi | Hemophilia | PK-guided Hemlibra dose reduction study. |
EmiSwitch | Hemophilia A | Biobank for patients who switch treatment to Hemlibra. |
e-Exercise | Hemophilia A and B | Face-to-face physiotherapy intervention integrated with the use of a mobile app. |
EUHASS | Hemophilia A and B | European registry to collect concomitant effects of hemophilia |
FRONTIER-2 | Adolescents and adults with hemophilia A | Therapeutic study to evaluate the safety and efficacy of MIM-8, a factor VIII by-passing agent |
FRONTIER-3 | Pediatrics with hemophilia A | Therapeutic study to evaluate the safety and efficacy of MIM-8, a factor VIII by-passing agent |
Gentherapie B | Adults with severe hemophilia B | Gene therapy study |
HOCUS-POCUS | Hemophilia A and B and Von Willebrand disease | Added value of point of care ultrasound |
Hope-B | Adults with severe hemophilia B | Gene therapy study |
HemoNED | All coagulation disorders | Dutch registry |
HCV | Adults with a coagulation disorder with a resolved hepatitis C infection | Study to the effect of antiviral treatment |
PedNet | Pediatric hemophilia A and B | European registry for inhibitor development |
PHYSNET2 | Hemophilia A and B | Predictors of change in physical functioning. |
PRIDES | Pregnant women with Von Willebrand's disease and hemopilia carriers | Pregnancy and Inherited Bleeding Disorders Study. |
PROFIT | Hemophilia A and B | Prospective study to immune tolerance induction therapy. |
PRO-RBDD | Rare coagulation deficiencies including FI and FXIII | European registry. |
Responsiveness | Hemophilia A and B | HAL-questionnaire for hip- or knee replacing surgeries or arthrodesis of the ankle. |
XTEND-Kids and XTEND-ed | Children with severe hemophilia A | Therapeutic study and its long-term follow-up study to the long-half life FVIII product BIVV001. |
WiN-Pro | Von Willebrand Disease | Prospective study on the bleeding tendency in VWD. |
Cooperation between physiotherapists in haemophilia treatment centers and primary care - Merel Timmer (World Congres Physiotherapy 2021)
In deze folder bevindt zich extra informatie door middel van een video. Scan de bovenste QR-code met uw telefoon om deze video te bekijken. Of bekijk de video via:
Do you have any questions about participation in one of our studies? Or do you want to get in touch with one of our researchers? Please feel free to contact the research team of the Van Creveldkliniek.